Search
Citations & References (1)
Invitrogen™
LentiArray™ CRISPR Positive Control Lentivirus, human HPRT
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive ControlRead more
| Catalog Number | Quantity |
|---|---|
| A32056 | 100 μL |
Catalog number A32056
Price (CNY)
4,165.00
Each
Quantity:
100 μL
Price (CNY)
4,165.00
Each
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive Control Lentivirus gRNA against HPRT is a highly efficient gRNA validated in multiple human cell lines that has achieved editing efficiencies of greater than 80%. It can be used to rapidly determine ideal delivery conditions in order to achieve maximum editing efficiency in your cell model of choice.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Control TypePositive Control
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCRISPR Positive Control Lentivirus
Quantity100 μL
Shipping ConditionDry Ice
PromoterU6
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
Contents & Storage
1 x 100 μL. Store (at -68°C to -85°C.)
Citations & References (1)
Citations & References
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific